ReviewJournal of Indian Society of Periodontology
Substance P-A neuropeptide regulator of periodontal disease pathogenesis and potential novel therapeutic entity: A narrative review.
Review in Journal of Indian Society of Periodontology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of the neuro-immune-bone axis in osteoporosis: from bone remodeling imbalance to multi-system interactions.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Substance P (SP), a neuropeptide primarily released by neurons, has emerged as a key player in the intricate network of factors governing periodontal inflammation, immune responses, bone metabolism, and tissue regeneration. Due to its multifaceted role, it may be explored for its potential participation in periodontal therapeutic strategies. The databases, PubMed/MEDLINE, and SCOPUS were searched for all published articles on SP, its role in inflammation, and periodontal disease. The following search terms, adapted to the specific database, were used; "substance p AND periodontal *" AND "therapeutics" and records were retrieved. All articles not pertaining to SP in periodontal health and disease were excluded from the study. The full texts of eligible articles were retrieved. Data on SP and its role in inflammation and in periodontal health, disease, and therapy were extracted and have been presented as a narrative review. SP manifests during inflammatory phase of periodontal disease and is one of the causes of bone loss. According to studies, the gingival crevicular fluid from areas with active periodontal disease and bone loss had the greatest levels of SP. These chemicals may linger long enough to trigger neurogenic inflammation and elicit pain in tissues that are vulnerable to it. SP expression during progression of periodontal disease might be a risk factor for individuals with systemic inflammatory diseases, such as chronic arthritis. However, SP may be manipulated to provide avenues for management of periodontal disease and thereby serve as therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.